Back to catalogue
№ 296 18 filings · 2021-10-13 → 2026-03-31

RAINBOW RARE EARTHS LIMITED

RBW
Basic Resources Share price 24.75p Market cap £173m Overall fit 210 /1000

Minimal direct AI-receiver exposure (rare earths feed EV/wind/defence, only tangentially robotics-AI hardware), pre-revenue so no realised operating leverage, valuation only modestly attractive on a heavily-risked basis, and a fragile single-project balance sheet requiring repeated equity issuance. Interesting critical-minerals story but a poor fit for the AI-beneficiary/operating-leverage strategy.

Fair value range 20p–35p Mid case · £192m
Absolute upside +10.9% vs current market cap
Conviction 2/5 confidence in fair call
Supports the call
  • Detailed Interim Study with post-tax NPV10 US$611m
  • Third-party validation via DFC US$50m and Ecora royalty
  • Peer P/NAV framework anchors range
Limits the call
  • No revenue, DFS not yet published
  • Material future equity dilution to fund US$326m capex
Methodology

Risked sum-of-parts P/NAV (Phalaborwa 0.3-0.5x, Uberaba 0.1-0.2x)

In one line · bull case

Strategically important ex-China source of magnet REE with low-cost phosphogypsum feedstock and US Government backing, trading at ~40% of un-risked attributable NPV.

In one line · biggest risk

Peak funding need of ~US$276m for Phalaborwa dwarfs the current £154m market cap, virtually guaranteeing multiple further equity raises and material per-share dilution.

Drivers
AI beneficiary 20 /100
Rare-earth magnets feed robotics/drones/defence but this is a critical-minerals green-transition play, not an AI picks-and-shovels beneficiary.
Operating leverage 50 /100
No current revenue; project shows classic 75% EBITDA-margin mining leverage to commodity price once in production but that is commodity leverage, not fixed-cost operating leverage.
Earnings vs expectations 50 /100
Not enough data — pre-revenue developer with no earnings guidance; milestone delivery mixed (technical hits, timeline slips).
Growth momentum 45 /100
Pre-revenue; project de-risking progressing but timeline repeatedly slips.
Moat 40 /100
Proprietary phosphogypsum-extraction IP, DFC/TechMet backing, first-mover — real but replicable over time.
Earnings quality 40 /100
Clean IFRS accounting but recurring going-concern language and material fair-value swings on the royalty liability.
Management quality 45 /100
Bennett has relevant mining execution background; multiple related-party arrangements (warrants, accommodation, consulting fees) worth monitoring.
Cyclicality 80 /100
Deeply cyclical — NdPr has traded below cash cost for extended periods; entirely commodity-price-driven.
Leverage 20 /100
Net cash post March 2026 raise; only material liability is the US$11m mark-to-market Ecora royalty.
Value-trap signals · 4
  • Repeated equity issuance at successively lower reference prices
  • Repeated DFS timeline slippage (2024→2025→2026) which mechanically raises the Ecora royalty rate
  • Going-concern uncertainty language in recent audit periods
  • Related-party transactions with CEO and Chairman-connected entities

Rainbow Rare Earths Limited (LSE: RBW) — Investment Research Note

Executive summary

Rainbow Rare Earths is a pre-production rare-earth developer pioneering the recovery of magnet rare earths (NdPr, Dy, Tb, Y) from phosphogypsum waste stacks, principally through its flagship Phalaborwa project in South Africa and, more recently, the Uberaba project in Brazil (49% JV with Mosaic). Across the period covered, the company has moved from concept to demonstrated pilot-plant production of a high-grade mixed rare-earth product, secured a US$50m DFC funding commitment via TechMet and a US$8.5m royalty from Ecora, and just recapitalised (US$14.6m at 20p, 31 March 2026) to complete the Phalaborwa DFS due H2 2026 2026-03-31 interim. The single most important valuation point today is that at 22p the market is capitalising Rainbow at roughly £154m for a project whose 100% post-tax NPV10 is US$611m — but that gap only closes if the DFS confirms the Interim Study economics and Rainbow can raise the ~US$326m capex without excessive dilution.

Fair value estimate

Fair-value range: 20p – 35p per share (mid ~27p), implying market cap £140m – £245m (mid £192m). vs current £154m → midpoint upside ~25%.

Methodology: risked sum-of-parts NAV. I take a P/NAV multiple approach appropriate for pre-production developers, then account for future funding dilution:

  • Phalaborwa (85% attributable): 100% post-tax NPV10 US$611m 2024-12 Interim Study, reaffirmed 2026-03-31. Rainbow's 85% ≈ US$519m ≈ £405m at 1.28 USD/GBP. Risked at 0.3x–0.5x for pre-DFS, permitting, financing risk → £120m–£200m.
  • Uberaba (49% attributable): 100% NPV10 US$916m 2026-03-31. Attributable US$449m ≈ £351m. Risked at 0.1x–0.2x (EA only, no JORC resource, PFS not started) → £35m–£70m.
  • Cash after March 2026 raise: ~US$16m = £12m; less ~£9m mark-to-market royalty liability.
  • Total risked NAV: ~£155m–£275m (20p–39p on 699.7m shares).
  • Dilution overlay: at ~US$276m residual capex (after DFC), further equity raises are essentially certain; if half-funded by equity at 25–30p, ~500m new shares would trebeat the share count post-build. This pulls the sensible range toward the lower end.

Blended fair value: 20p – 35p, mid ~27p.

Sector context

Basic Resources / mining, specifically critical minerals — an unusual sub-sector given the reprocessing model (chemical extraction from phosphogypsum, not hard-rock mining). Quality: pre-revenue single-project developer with a novel proprietary flowsheet; below-typical for the sector on cash generation, in line on capital intensity, above-typical on ESG positioning (site remediation embedded). Listed peers: MP Materials (NYSE: MP) — vertically integrated US producer with a US$110/kg floor deal explicitly referenced in Rainbow's filings; Lynas Rare Earths (ASX: LYC) — largest ex-China producer, similarly Government-backed; Iluka Resources (ASX: ILU) — building a refinery in Australia with sovereign backing.

Investment thesis

  • Strategic asset in a bifurcated market with policy tailwinds. The US MP Materials/DoD US$110/kg floor and Chinese heavy-REE export controls have pushed EU/US Dy, Tb and Y prices to 3–25x Chinese equivalents, materially improving the ex-China economics of Phalaborwa's SEG+ product 2026-03-31 interim. DFC/TechMet US$50m commitment de-risks the equity ticket to build 2025-03-19 interim.
  • Uniquely low-cost feedstock. Phalaborwa is a chemical processing operation on already-cracked phosphogypsum, avoiding mining, crushing, grinding and cracking costs, giving an Interim Study post-tax IRR of 38% and 2.0-year payback at base-case pricing 2024-10-23 ARA / 2025-03-19 interim. Pilot plant now producing 78% TREO product 2026-03-31.
  • Optionality on Uberaba adds a second leg. Post-Mosaic EA delivered a headline US$916m NPV10 with 45% IRR at a materially higher grade than Phalaborwa (~80% higher TREO), giving Rainbow a plausible second project of equivalent or greater scale 2026-03-31 interim.

Key risks

  • Financing / dilution risk (High). Peak funding need c.US$276m for Phalaborwa alone after DFC; at a £154m mcap this implies equity raises far exceeding today's capitalisation and material dilution to per-share value 2026-03-31 interim & 2025-03-19 interim.
  • Project-definition risk (High). DFS not yet published; the interim study assumes a not-yet-piloted SX separation stage; separation flowsheet still being evaluated (may sell MREP at only 70–75% payability instead of separated oxides) 2026-03-31 interim. Interim P&L absorbed a US$3.9m fair-value hit on the royalty liability in H1 2026 alone — evidence of how sensitive valuation is to inputs.
  • REE price cycle (High). NdPr traded below the average industry cost of production Q2 2023 through mid-2025, and the recent price recovery is partly policy-driven; if China loosens export controls or floor pricing is not extended, project economics compress rapidly 2026-03-31 & 2025-03-19.

Operating leverage

At current scale Rainbow has no revenue and effectively no operating leverage — the ~US$3.9m half-year operating loss reflects a fixed corporate cost base of ~US$3.5m/year plus research costs 2026-03-31 interim P&L. Once Phalaborwa is in production, the project shows classic high-fixed-cost mining leverage: 75% EBITDA margin at Interim Study base case, average EBITDA US$180m/yr on Rainbow's ~US$611m NPV base 2024-10-23 ARA. Every US$10/kg move in NdPr against the US$110/kg base case adds roughly US$18m/year of EBITDA on Phalaborwa production (10,000tpa MREP → ~1,800tpa NdPr) — so at commodity prices 20% above the base case, project EBITDA would rise ~US$40m/yr, or ~20%. This is meaningful cyclical leverage but it is commodity leverage, not the kind of "high-fixed-cost software beats and profit trebles" leverage the strategy is targeting.

Value-trap signals

  • Serial equity issuance at falling reference prices (Oct 2021 15p; Sept 2023 15p; July 2024 11.4p to Ecora; March 2026 20p) — dilution is structural to the model.
  • Repeated DFS slippage: 2024 interim said DFS "end of 2024"; 2025 interim said "end of 2025"; 2026 interim now says "later this year". Each slip pushes the Ecora royalty rate higher (0.85% → 0.95% → 1.10%) royalty notes.
  • Related-party items worth watching: CEO's Pipestone warrant liability, CEO's Hague House Management (accommodation reimbursements previously undisclosed), Chairman's Magna/Kinsella consulting fees.
  • Going-concern language appeared in FY24 accounts (2025-03-19 interim); resolved for now by the March 2026 raise but reliance on capital markets is continuous.

Earnings vs. expectations

Not meaningful for a pre-revenue developer — there is no earnings guidance to track. The relevant "expectations" track record is milestone delivery: on this basis Rainbow has consistently met technical milestones (pilot production of MREP, resource upgrades, EA at Uberaba) but has repeatedly missed timeline commitments on the Phalaborwa DFS. Financial results are mechanically in line with a US$3–4m/yr cash-burn business.

Conviction

Conviction: 2 (low). The fair-value range is wide because it depends on (i) an unfinished DFS, (ii) a commodity price where 3-year historical volatility exceeds 100%, (iii) a dilution path that hasn't happened yet, and (iv) an entirely un-priced Uberaba PFS. Anchoring factors: the Interim Study is detailed and third-party endorsed (Ecora, DFC/TechMet due diligence); market-cap-to-NPV framework is standard for the sector; comparable developers (MP, Lynas, Iluka) provide sensible bounds. Limiting factors: no revenue, no earnings, no DFS, and my P/NAV multiple is a judgement rather than a directly observable market input.

Filings consulted · 18

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-03-31Interim Results For Six Months TO 31 December 20252026-03-31_9500041_interim-results-for-six-months-to-31-december-2025.md0.90
  2. 2026-03-17Publication OF New Investor Presentation2026-03-17_9477030_publication-of-new-investor-presentation.md0.70
  3. 2025-10-27Publication OF Annual Report And Notice OF Agm2025-10-27_9195960_publication-of-annual-report-and-notice-of-agm.md0.81
  4. 2025-03-19Interim Results For 6 Months TO 31 December 20242025-03-19_8785736_interim-results-for-6-months-to-31-december-2024.md0.58
  5. 2024-11-07Result OF Agm2024-11-07_8536773_result-of-agm.md0.20
  6. 2024-10-23Publication OF Annual Report And Notice OF Agm2024-10-23_8503805_publication-of-annual-report-and-notice-of-agm.md0.62
  7. 2024-03-28Interim Results2024-03-28_8111037_interim-results.md0.41
  8. 2023-10-31Publication OF Annual Report And Notice OF Agm2023-10-31_7850164_publication-of-annual-report-and-notice-of-agm.md0.43
  9. 2023-10-05Admission OF First Tranche OF Placing Shares2023-10-05_7797501_admission-of-first-tranche-of-placing-shares.md0.32
  10. 2023-07-18Investor Presentation2023-07-18_7638282_investor-presentation.md0.17
  11. 2023-03-31Interim Results For Six Months TO 31 December 20222023-03-31_7380070_interim-results-for-six-months-to-31-december-2022.md0.23
  12. 2023-01-10Investor Presentation2023-01-10_7345747_investor-presentation.md0.17
  13. 2022-10-27Publication OF Annual Report Amp Notice OF Agm2022-10-27_7160877_publication-of-annual-report-amp-notice-of-agm.md0.24
  14. 2022-07-07Notice OF Investor Presentation2022-07-07_6920492_notice-of-investor-presentation.md0.17
  15. 2022-03-17Interim Results For Six Months TO 31 December 20212022-03-17_6968597_interim-results-for-six-months-to-31-december-2021.md0.23
  16. 2021-10-29Publication OF Ara And Notice OF Agm2021-10-29_6622402_publication-of-ara-and-notice-of-agm.md0.07
  17. 2021-10-14Investor Presentation2021-10-14_6811380_investor-presentation.md0.17
  18. 2021-10-13Placing Raises 6 435 Million AT 15p Per Share2021-10-13_6766238_placing-raises-6-435-million-at-15p-per-share.md0.17

This research note was authored by a large language model after reading 18 regulatory filings published between 2021-10-13 and 2026-03-31. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.